聯絡服務專員 Todd Ting：09：00~18：00 (GMT+8)
slavia10@gmail.com
en
 -ESPOIR NOVA International Medical Service-

Transcatheter Aortic Valve Implantation (TAVI) 

Introduction to Aortic Stenosis and TAVI Procedure

With the global aging population, the number of aortic stenosis cases has been increasing. Among individuals aged 75 and older, approximately 3.4% suffer from severe aortic stenosis. When symptoms such as chest pain, syncope, and heart failure appear, the standard treatment is surgical aortic valve replacement. However, over 30% of patients are unable to undergo open-heart surgery due to advanced age or comorbidities. Once symptoms of severe aortic stenosis develop, patients who only receive medication without surgery face a one-year mortality rate as high as 50%, Five-year survival rate is close to zero—making the condition as life-threatening as cancer.

Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive alternative for patients who are unsuitable for conventional surgery or face high surgical risks.

Medical Achievements

Six Transcatheter Access Routes
The team can perform valve implantation via six different access routes: the femoral artery, subclavian artery, ascending aorta, apex, abdominal aorta, and carotid artery. This provides treatment options for patients with peripheral vascular disease and significantly reduces the risk of major vascular rupture and bleeding.

  • Major Vascular Complication Rate: 3.4%, lower than the 4.1%–10.9% reported in the U.S. and Europe.

  • Stroke Rate: 1.3%, well below the international average of 1.5%–4.0%. If a stroke occurs during the procedure, the 30-day mortality rate increases by 3.5 times.

  • Moderate or Severe Paravalvular Leak: 2.0%, significantly lower than the 5.1%–16.2% observed internationally. All patients undergo comprehensive preoperative imaging (e.g., transthoracic and transesophageal echocardiography, cardiac catheterization, and 3D CT reconstruction), followed by thorough planning discussions in pre-procedure meetings.

  • Permanent Pacemaker Implantation Rate: 4.1%, much lower than the global rate of 10%–26.3%. This reduction minimizes hospital stay, complications, and readmissions due to bradycardia.

  • Postoperative Mortality:

    • 30-day mortality rate: 5.4% (lower than the international range of 4.5%–8.4%)

    • One-year mortality rate: 14.0% (significantly lower than the 18.4%–24.3% reported in the U.S. and Europe)